Citations 2
Outcome Predictors of Radical Prostatectomy Followed by Adjuvant Androgen Deprivation in Patients with Clinical High Risk Prostate Cancer and pT3 Surgical Margin Positive Disease
Spahn, Martin , Briganti, Alberto, Capitanio, Umberto , Kneitz, Burkhard , Gontero, Paolo , Karnes, Jeffrey , Schubert, Maria , Montorsi, Francesco , Scholz, Claus Jürgen , Bader, Pia, Poppel, Hein van, Joniau, Steven , Larcher, Alessandro , Joniau, Steven , Gontero, Paolo
Journal of Urology | May 12, 2012 | Volume: 188 | Issue: 1 | Pages: 84-90
The Role of Adjuvant Hormonal Treatment after Surgery for Localized High-Risk Prostate Cancer: Results of a Matched Multiinstitutional Analysis
Schubert, Maria , Joniau, Steven , Gontero, Paolo , Kneitz, Susanne , Scholz, Claus Jürgen , Kneitz, Burkhard , Briganti, Alberto , Karnes, R. Jeffrey , Tombal, Bertrand , Walz, Jochen , Marchioro, G. , Bader, Pia, Bangma, Chris, Frohneberg, D., Graefen, Markus , Schröder, Fritz H., Cangh, Paul Van, Poppel, Hein van, Spahn, Martin , Hsu, Chao‐Yu , Poppel, Hein van, Joniau, Steven , Gontero, Paolo
Advances in Urology | January 31, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-6
Introduction. To assess the role of adjuvant androgen deprivation therapy (ADT) in high-risk prostate cancer patients (PCa) after surgery.Materials and Methods.The analysis case matched 172 high-risk PCa patients with positive section margins or non-organ confined disease and negative lymph nodes to receive adjuvant ADT (group 1,n=86) or no adjuvant ADT (group 2,n=86).Results. Only 11.6% of the patients died, 2.3% PCa related. Estimated 5–10-year clinical progression-free survival was 96.9% (94.3%) for group 1 and 73.7% (67.0%) for group 2, respectively. Subgroup analysis identified men with T2/T3a tumors at low-risk and T3b margins positive disease at higher risk for progression.Conclusion. Patients with T2/T3a tumors are at low-risk for metastatic disease and cancer-related death and do not need adjuvant ADT. We identified men with T3b margin positive disease at highest risk for clinical progression. These patients benefit from immediate adjuvant ADT.